Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.
From its newest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment extends pharmacy benefit management strategies. The Long or retail Term Care segment has offering of prescribed drugs and assortment of general merchandise.
The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and associated services, including medical, pharmacy, dental, behavioural health, healthcare relief capabilities. The Corporate segment involves in offering administrative services and management. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.